BioSpace News Archive

Secarna Pharmaceuticals GmbH & Co. KG announced today the publication of compelling new preclinical data supporting the use of ASOs for the treatment of inflammatory diseases in the peer-reviewed journal, The Journal of Immunology.

ProSomnus, Inc. will report its strong second quarter financial results prior to market open on Thursday, August 3, 2023.

Intelligent Bio Solutions Inc. today announced it has signed a distribution agreement for its Intelligent Fingerprinting Drug Screening System with Chile-based company TSCOM SPA , increasing the product’s availability across South America.

NeuroSense Therapeutics Ltd. today provided an update from its CEO, Alon Ben-Noon, on the Company’s clinical and operational developments during the second quarter of 2023.

Charles River Associates today announced that Sheldon Ng has joined the company’s Life Sciences Practice as a vice president.

DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2023 financial results after market close on Thursday, July 27, 2023.

Incannex Healthcare Limited is pleased to announce that Incannex has received approval from Bellberry Human Research Ethics Committee to commence a bioavailability/ bioequivalence (‘BA/BE’) clinical trial on IHL-42X, the Company’s proprietary drug product for treatment of obstructive sleep apnoea.

Moleculin Biotech, Inc. today announced that Walter Klemp , President and Chief Executive Officer and Jon Foster, Executive VP & Chief Financial Officer of Moleculin, will participate in the Virtual Investor Summer Spotlight Series on Wednesday, July 12, 2023 at 3:00 PM ET.

TellBio, Inc., a development stage biotechnology company focused on revolutionizing detection of cancer through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx System, announces two publications that demonstrate the utility of CTC molecular analyses in patients with prostate cancer or advanced breast cancer.

MedRhythms today announced that MR-001, the company’s evidence-based neurorehabilitation system to improve walking and ambulation in adults with chronic stroke walking deficits, has been listed as a Class II medical device with the U.S. Food and Drug Administration (FDA).